LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
LaunchKC lands keynote speaker from NASA; Techweek queries two Google developer advocates
Pitch Day for LaunchKC is expected to lift off next month with an opening keynote address from NASA executive Kira Blackwell. Remarks are expected to delve into NASA iTech, a year-long effort to find innovative ideas that address challenges and fill gaps in five critical areas identified by the space agency as having a potential impact…
CBD startup: Young father sees Native Hemp Co. as the launch of a health revolution
At 21 years old, Rich Dunfield IV felt like an absentee father, he said. Struck in his prime with painful ailments after a tick bite — nerve and belly problems, anxiety and depression — he was home but not present. “My entire life was rooted in fatherhood. I started young, but I embraced it. Lyme…
New Lawrence Blade & Timber just the edge of Swell Spark’s ongoing brand evolution
A newly opened Lawrence Blade & Timber — well-positioned on the college town’s popular Massachusetts Street — features the axe-throwing brand’s first “retailtainment” concept. It’s a reflection of parent company Swell Spark’s ongoing push to keep Blade & Timber (as well as the Choir Bar and Breakout businesses) fresh amid an increasingly crowded experience-based entertainment…
25th anniversary: Roasterie founder Danny O’Neill recalls humble start with just ‘nickels and pickles’
Brewed in a recession, Danny O’Neill wasn’t sure The Roasterie would sell a single cup of coffee, let alone percolate into an iconic Kansas City brand, the founder said as he reflected on the regional coffee titan’s 25th anniversary. “The only idea I had was coffee,” O’Neill said of his decision to jump ship from…